ArticleFrontiers in endocrinology2026
Prevalence of clinical manifestations among patients with hypophosphatasia in Central and Eastern European countries.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mini-abstract: Hypophosphatasia (HPP) is a rare systemic disorder with impaired bone mineralization. In 49 Central and Eastern European patients, chronic pain, fractures, deformities, and calcifying periarthritis were frequent. Most had low TN-ALP; only one received asfotase alfa. Findings highlight underdiagnosis, high symptom burden, and need for improved care. Introduction: Hypophosphatasia (HPP) is a rare, potentially life-threatening, progressive, systemic, inherited metabolic disorder caused by loss-of-function variants in the Aim: The objective of this study was to evaluate the prevalence of HPP in the Central and Eastern European (CEE) region and to assess the frequency of its clinical manifestations. Patients and methods: A cross-sectional study was conducted on 49 patients with clinically and genetically confirmed HPP. Detailed clinical information was available for 34 patients from five CEE countries. Results: The analyzed cohort consisted of 14 males and 20 females, with a mean age of 51 years, regardless onset. A total of 33 patients (97%) exhibited TN-ALP levels below the reference range. Only one patient received treatment with asfotase alfa. Chronic musculoskeletal pain was reported by 25 patients (73%), while tooth loss, fractures, and bone deformities were observed in 26%, 44%, and 18% patients, respectively. One patient had a bone mineral density (BMD) in the osteoporotic range, and three patients had a trabecular bone score (TBS) ≤1.23. Other clinical manifestations included calcifying periarthritis (7 patients), seizures (3), nephrocalcinosis (3), hypercalcemia (3), kidney stones (2), ectopic calcifications (1), and pseudogout (1). Conclusion: This study, based on one of the largest reported cohorts of HPP patients, highlights that chronic pain is the most prevalent symptom. Bone-related complications, such as fractures and deformities, and joint-related conditions, particularly calcifying periarthritis, are also frequent. These findings emphasize the need for greater awareness of HPP, along with dedicated research efforts to enhance patient care and improve access to effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.